We can highlight the next thriving fund investment areas, such as Health Diagnostics, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Singlera Genomics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
The usual things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2018. The fund is constantly included in less than 2 investment rounds annually.
The usual cause for the fund is to invest in rounds with 5 partakers. Despite the UCF Medical Investment, startups are often financed by Lilly Asia Ventures, Green Pine Capital Partners, CD Capital. The meaningful sponsors for the fund in investment in the same round are Prosperico Ventures, Lilly Asia Ventures, Jointown Pharmaceutical Group.
Related Funds
| Fund Name | Location |
| 100X | Boston, Massachusetts, United States |
| AzurInvest | - |
| BancBoston Capital | Boston, Massachusetts, United States |
| Bollinger Investment Group | - |
| Boulas Ventures | France, Ile-de-France, Paris |
| Endicott Group | New York, New York, United States |
| ePartners | Irving, Texas, United States |
| Fortimo Group | Sankt Gallen, Sankt Gallen, Switzerland |
| Fucheng Touzi | China, Guangdong Province, Guangzhou City |
| Headland Capital Partners | China, Hong Kong, Hong Kong Island |
| Indigo Partners | Arizona, Phoenix, United States |
| Innova Capital Consultoria Ltda (Brazil) | Brazil, São Paulo, Sao Paulo |
| Kuai Lian Guwen | Beijing, Beijing, China |
| Maricopa County Industrial Development Authority | Arizona, Phoenix, United States |
| McNair Group | Atlanta, Georgia, United States |
| Michigan Capital Advisors | - |
| Northern Gulf Partners | New York, New York, United States |
| Yuce Biological Technology | China, Guangdong, Shenzhen |
| ZIG Capital | New York, New York, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Singlera Genomics | $60M | 27 Mar 2018 | San Diego, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Singlera Genomics | $60M | 27 Mar 2018 | San Diego, California, United States |
